(3b,5b,7a,12a)- 7,12- dihydroxy- 3- (2- ((4- ((11b,17b)- 17- hydroxy- 3- oxo- 17- prop- 1- ynylestra- 4,9- dien- 11- yl) phenyl)(methyl)amino)ethoxy)cholan- 24- oic acid

structure in first source

Also Known As:

A-348441

Networked: 3 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Polycyclic Compounds: 6
- Fused-Ring Compounds
  - Steroids: 70059
Hormones, Hormone Substitutes, and Hormone Antagonists
- Hormones: 80400
  - Adrenal Cortex Hormones: 62914
    - 17-Ketosteroids: 611
      - Estrone: 1105
        (3b,5b,7a,12a)-7,12-dihydroxy-3-(2-((4-((11b,17b)-17-hydroxy-3-oxo-17-prop-1-ynylestra-4,9-dien-11-yl) phenyl)(methyl)amino)ethoxy)cholan-24-oic acid: 3
  - Gonadal Hormones: 716
    - Gonadal Steroid Hormones: 7657
      - Estradiol Congeners: 358
        Estrone: 1105
        (3b,5b,7a,12a)-7,12-dihydroxy-3-(2-((4-((11b,17b)-17-hydroxy-3-oxo-17-prop-1-ynylestra-4,9-dien-11-yl) phenyl)(methyl)amino)ethoxy)cholan-24-oic acid: 3

Experts

1.	Mika, Amanda: 2 articles (03/2007 - 07/2005)
2.	Ohman, Lars: 2 articles (03/2007 - 07/2005)
3.	Wilcox, Denise: 2 articles (03/2007 - 07/2005)
4.	Zinker, Bradley: 2 articles (03/2007 - 07/2005)
5.	von Geldern, Thomas W: 2 articles (03/2007 - 07/2005)
6.	Andrew, Ruth: 1 article (01/2019)
7.	Livingstone, Dawn E W: 1 article (01/2019)
8.	Mak, Tracy C S: 1 article (01/2019)
9.	Nixon, Mark: 1 article (01/2019)
10.	Walker, Brian R: 1 article (01/2019)

Related Diseases

1.	Weight Gain 01/01/2019 - "In a second model of 5α-reductase inhibition using dutasteride and hepatic GR antagonism with A-348441 attenuated the excess weight gain resulting from dutasteride (mean ± SEM, 7.03 ± 0.5 vs 2.13 ± 0.4 g; dutasteride vs dutasteride plus A-348441; P < 0.05) and normalized the associated hyperinsulinemia after glucose challenge (area under the curve, 235.9 ± 17 vs 329.3 ± 16 vs 198.4 ± 25 ng/mL/min; high fat vs high fat plus dutasteride vs high fat plus dutasteride plus A-348441, respectively; P < 0.05). "
2.	Insulin Resistance 03/01/2007 - "In conclusion, these results indicate that A-348441 increases insulin sensitivity at both the liver and peripheral tissues, leading toward a normalization of the insulin resistant state. "
3.	Hypoglycemia (Reactive Hypoglycemia) 03/01/2007 - "After 1 week of sub-long-term dosing, fasting glucose levels were reduced dose-dependently with A-348441 vs vehicle (-8%, not significant; -14%, -20%, and -25%, P < .05, at 3, 10, 30, and 100 mg/kg, respectively) with no observed hypoglycemia or change in fasting insulin levels. "
4.	Hyperinsulinism (Hyperinsulinemia) 01/01/2019 - "In a second model of 5α-reductase inhibition using dutasteride and hepatic GR antagonism with A-348441 attenuated the excess weight gain resulting from dutasteride (mean ± SEM, 7.03 ± 0.5 vs 2.13 ± 0.4 g; dutasteride vs dutasteride plus A-348441; P < 0.05) and normalized the associated hyperinsulinemia after glucose challenge (area under the curve, 235.9 ± 17 vs 329.3 ± 16 vs 198.4 ± 25 ng/mL/min; high fat vs high fat plus dutasteride vs high fat plus dutasteride plus A-348441, respectively; P < 0.05). "
5.	Type 2 Diabetes Mellitus (MODY) 07/01/2005 - "Overall, A-348441 demonstrates that an LSGRA is sufficient to reduce elevated HGO and normalize blood glucose and may provide a new therapeutic approach for the treatment of type 2 diabetes."

Related Drugs and Biologics

1.	Glucose (Dextrose)
2.	Oxidoreductases (Dehydrogenase)
3.	Insulin (Novolin)
4.	Blood Glucose (Blood Sugar)
5.	Dutasteride (Avodart)